CN109715152A - 医治感染的方法 - Google Patents

医治感染的方法 Download PDF

Info

Publication number
CN109715152A
CN109715152A CN201780040800.8A CN201780040800A CN109715152A CN 109715152 A CN109715152 A CN 109715152A CN 201780040800 A CN201780040800 A CN 201780040800A CN 109715152 A CN109715152 A CN 109715152A
Authority
CN
China
Prior art keywords
infection
subject
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780040800.8A
Other languages
English (en)
Chinese (zh)
Inventor
M.泰珀
D.W.吉尔罗伊
M.莫特瓦尼
T.L.邦菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corbus Pharmaceuticals Inc
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Publication of CN109715152A publication Critical patent/CN109715152A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201780040800.8A 2016-04-29 2017-04-28 医治感染的方法 Pending CN109715152A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329514P 2016-04-29 2016-04-29
US62/329514 2016-04-29
US201662400503P 2016-09-27 2016-09-27
US62/400503 2016-09-27
US201762470419P 2017-03-13 2017-03-13
US62/470419 2017-03-13
PCT/US2017/030236 WO2017190070A1 (en) 2016-04-29 2017-04-28 Methods for the treatment of infection

Publications (1)

Publication Number Publication Date
CN109715152A true CN109715152A (zh) 2019-05-03

Family

ID=60161141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780040800.8A Pending CN109715152A (zh) 2016-04-29 2017-04-28 医治感染的方法

Country Status (7)

Country Link
US (2) US20190133995A1 (enExample)
EP (1) EP3448377A4 (enExample)
JP (1) JP2019515927A (enExample)
CN (1) CN109715152A (enExample)
AU (1) AU2017258765A1 (enExample)
CA (1) CA3022391A1 (enExample)
WO (1) WO2017190070A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240212A1 (ja) * 2018-06-14 2019-12-19 株式会社カネカ 薬学的活性成分を含む製剤
WO2022204014A1 (en) * 2021-03-25 2022-09-29 Per Os Biosciences, Llc. Compositions and methods for treating coronavirus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192732A (zh) * 1995-06-21 1998-09-09 萨诺费公司 Cb2受体拮抗剂化合物
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
CN1939917A (zh) * 1999-03-22 2007-04-04 免疫力药品有限公司 大麻酯衍生物及其药用
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US20110301078A1 (en) * 2008-06-25 2011-12-08 Schetz John A Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
CN105228613A (zh) * 2013-02-12 2016-01-06 柯巴斯医药有限公司 超纯的四氢大麻酚-11-羧酸

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586767B2 (en) * 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
WO2004058251A1 (en) * 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20150328198A1 (en) * 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192732A (zh) * 1995-06-21 1998-09-09 萨诺费公司 Cb2受体拮抗剂化合物
CN1939917A (zh) * 1999-03-22 2007-04-04 免疫力药品有限公司 大麻酯衍生物及其药用
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US20110301078A1 (en) * 2008-06-25 2011-12-08 Schetz John A Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
CN105228613A (zh) * 2013-02-12 2016-01-06 柯巴斯医药有限公司 超纯的四氢大麻酚-11-羧酸

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BONFIELD, T.L.: "Resunab,a CB2 agonist for the treatment of CF", 《 PEDIATRIC PULMONOLOGY》 *

Also Published As

Publication number Publication date
CA3022391A1 (en) 2017-11-02
EP3448377A4 (en) 2019-12-25
US20200405687A1 (en) 2020-12-31
EP3448377A1 (en) 2019-03-06
AU2017258765A1 (en) 2018-11-29
US20190133995A1 (en) 2019-05-09
JP2019515927A (ja) 2019-06-13
WO2017190070A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
Zarif et al. Cochleates: new lipid-based drug delivery system
CN107249584A (zh) 用于抑制真菌感染的组合物和方法
CN102223876A (zh) 纳米乳剂治疗性组合物及其使用方法
Nagaraj et al. Potent antifungal agents and use of nanocarriers to improve delivery to the infected site: A systematic review
CN109394689A (zh) 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
WO2016131100A1 (en) Methods of treating infectious diseases
Wu et al. Progress of polymer-based strategies in fungal disease management: Designed for different roles
JP2019513837A (ja) フィトグリコーゲンナノ粒子を含む抗感染症組成物
CN103957907B (zh) 抗真菌剂
Adwani et al. Nano-enhanced antifungal therapy in diabetic patients with candidiasis
CN109715152A (zh) 医治感染的方法
Allendoerfer et al. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis
US11998615B2 (en) Functionalized nanoparticles and their use in treating bacterial infections
WO2017038872A1 (ja) 抗真菌活性を有する組成物
CN107920994A (zh) 用于治疗目的的板层小体的组合物和方法
Kusumawardani et al. The effect of ethanolic extract of propolis on skin manifestation and skin tissue necrosis in cutaneous anthrax animal model
HK40008280A (en) Methods for the treatment of infection
KR20200066664A (ko) 세균 감염증을 치료하는 방법
Oves et al. Fungal Infection: The Hidden Enemy?
US20220409651A1 (en) Anti-fungal compositions and methods for using same
WO2009137611A2 (en) Treatment of pulmonary fungal infection with voriconazole via inhalation
Antonissen et al. Antifungal Drugs
Marques et al. Nanotherapeutics in Candidiasis
WO2024211753A1 (en) Pharmaceutical compositions for wound care
JP2021134176A (ja) ムーコル症治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008280

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190503